Código QR (código de barras bidimensional)

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports

ObjectiveDespite the promising efficacy and tolerability of alectinib in treating advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC), the role of alectinib in neoadjuvant setting remains understudied in ALK-rearranged resectable lung cancer.MethodsOur report concer...

ver descrição completa

Na minha lista:
Principais autores: Liang Shi, Shuhong Gao, Li Tong, Qiyi Meng, Shijie Zhou, Daping Yu, Yujie Dong, Zhe Liu
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2023-06-01
coleção:Frontiers in Oncology
Assuntos:
lung adenocarcinoma
ALK rearrangement
neoadjuvant therapy
alectinib
pathological complete response
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fonc.2023.1120511/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados